Sihuan Pharma has started a China clinical trial of favipiravir, an RNA polymerase inhibitor, to treat COVID-19. The oral drug was co-developed by Sihuan and the Institute of Microbiology Epidemiology of the Academy of Military Medical Sciences. In 2014, Sihuan's tests of favipiravir showed it was an effective treatment for Ebola. China's Human Genetic Resources Management Office reviewed and approved the COVID-19 trial in one day. If favipiravir proves effective against the COVID-19 virus, Sihuan promised to distribute it for free. More details....
Stock Symbol: (HK: 0460)
Share this with colleagues:
Original Article: Sihuan Pharma Starts China Trials of Favipiravir to Treat COVID-19